Pardis Azmoon

539 total citations
18 papers, 389 citations indexed

About

Pardis Azmoon is a scholar working on Molecular Biology, Immunology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Pardis Azmoon has authored 18 papers receiving a total of 389 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 8 papers in Immunology and 6 papers in Cellular and Molecular Neuroscience. Recurrent topics in Pardis Azmoon's work include Prion Diseases and Protein Misfolding (4 papers), Nerve injury and regeneration (4 papers) and Protease and Inhibitor Mechanisms (4 papers). Pardis Azmoon is often cited by papers focused on Prion Diseases and Protein Misfolding (4 papers), Nerve injury and regeneration (4 papers) and Protease and Inhibitor Mechanisms (4 papers). Pardis Azmoon collaborates with scholars based in United States, Italy and China. Pardis Azmoon's co-authors include Steven L. Gonias, Elisabetta Mantuano, Coralie Brifault, Andrew S. Gilder, Michael S. Lam, W. Marie Campana, Cristina Zalfa, Lipsa Das, Donald Pizzo and Christina J. Sigurdson and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Nature Communications.

In The Last Decade

Pardis Azmoon

18 papers receiving 388 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Pardis Azmoon United States 11 164 107 86 74 55 18 389
Michael S. Lam United States 9 152 0.9× 75 0.7× 103 1.2× 63 0.9× 53 1.0× 13 365
Hea Nam Hong South Korea 13 217 1.3× 35 0.3× 56 0.7× 66 0.9× 54 1.0× 24 434
Benjamin N. Ostendorf Germany 11 221 1.3× 121 1.1× 117 1.4× 40 0.5× 22 0.4× 19 493
M. Gorovoy United States 8 226 1.4× 90 0.8× 52 0.6× 28 0.4× 118 2.1× 10 489
Annalisa Morano Italy 11 376 2.3× 63 0.6× 108 1.3× 33 0.4× 26 0.5× 14 545
Alexandra Makarova United States 7 159 1.0× 53 0.5× 117 1.4× 85 1.1× 90 1.6× 9 399
Midori Koyanagi Japan 15 275 1.7× 70 0.7× 110 1.3× 48 0.6× 31 0.6× 23 527
Ehsan Ghayoor Karimiani Iran 12 180 1.1× 123 1.1× 33 0.4× 22 0.3× 40 0.7× 46 476
Melissa Geyer United States 6 189 1.2× 42 0.4× 83 1.0× 32 0.4× 79 1.4× 7 509
Paul Coleman Australia 16 229 1.4× 87 0.8× 60 0.7× 16 0.2× 93 1.7× 20 494

Countries citing papers authored by Pardis Azmoon

Since Specialization
Citations

This map shows the geographic impact of Pardis Azmoon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pardis Azmoon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pardis Azmoon more than expected).

Fields of papers citing papers by Pardis Azmoon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pardis Azmoon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pardis Azmoon. The network helps show where Pardis Azmoon may publish in the future.

Co-authorship network of co-authors of Pardis Azmoon

This figure shows the co-authorship network connecting the top 25 collaborators of Pardis Azmoon. A scholar is included among the top collaborators of Pardis Azmoon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pardis Azmoon. Pardis Azmoon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Martellucci, Stefano, Masaki Norimoto, Donald Pizzo, et al.. (2024). Axon‐derived PACSIN1 binds to the Schwann cell survival receptor, LRP1, and transactivates TrkC to promote gliatrophic activities. Glia. 72(5). 916–937. 2 indexed citations
2.
Mantuano, Elisabetta, et al.. (2023). An LRP1-binding motif in cellular prion protein replicates cell-signaling activities of the full-length protein. JCI Insight. 8(15). 4 indexed citations
4.
Bernareggi, Davide, Qi Xie, Briana C. Prager, et al.. (2022). CHMP2A regulates tumor sensitivity to natural killer cell-mediated cytotoxicity. Nature Communications. 13(1). 1899–1899. 46 indexed citations
6.
Gonias, Steven L., et al.. (2022). Cellular prion protein in human plasma–derived extracellular vesicles promotes neurite outgrowth via the NMDA receptor–LRP1 receptor system. Journal of Biological Chemistry. 298(3). 101642–101642. 5 indexed citations
8.
Mantuano, Elisabetta, et al.. (2021). A Soluble PrPC Derivative and Membrane-Anchored PrPC in Extracellular Vesicles Attenuate Innate Immunity by Engaging the NMDA-R/LRP1 Receptor Complex. The Journal of Immunology. 208(1). 85–96. 10 indexed citations
9.
Brifault, Coralie, Haylie Romero, Pardis Azmoon, et al.. (2020). Deletion of the Gene Encoding the NMDA Receptor GluN1 Subunit in Schwann Cells Causes Ultrastructural Changes in Remak Bundles and Hypersensitivity in Pain Processing. Journal of Neuroscience. 40(47). 9121–9136. 24 indexed citations
10.
Mantuano, Elisabetta, et al.. (2020). A soluble derivative of PrPC activates cell-signaling and regulates cell physiology through LRP1 and the NMDA receptor. Journal of Biological Chemistry. 295(41). 14178–14188. 12 indexed citations
11.
Das, Lipsa, et al.. (2019). Tissue-type plasminogen activator selectively inhibits multiple toll-like receptors in CSF-1-differentiated macrophages. PLoS ONE. 14(11). e0224738–e0224738. 13 indexed citations
12.
Pontecorvi, Paola, Cristina Zalfa, Pardis Azmoon, et al.. (2019). Fibrinolysis protease receptors promote activation of astrocytes to express pro-inflammatory cytokines. Journal of Neuroinflammation. 16(1). 257–257. 23 indexed citations
13.
Zalfa, Cristina, Pardis Azmoon, Elisabetta Mantuano, & Steven L. Gonias. (2019). Tissue-type plasminogen activator neutralizes LPS but not protease-activated receptor-mediated inflammatory responses to plasmin. Journal of Leukocyte Biology. 105(4). 729–740. 19 indexed citations
14.
Garofalo, Tina, Alberto Ferri, Maurizio Sorice, et al.. (2018). Neuroglobin overexpression plays a pivotal role in neuroprotection through mitochondrial raft-like microdomains in neuroblastoma SK-N-BE2 cells. Molecular and Cellular Neuroscience. 88. 167–176. 18 indexed citations
15.
Gonias, Steven L., et al.. (2018). PAI1 blocks NMDA receptor-mediated effects of tissue-type plasminogen activator on cell signaling and physiology. Journal of Cell Science. 131(14). 10 indexed citations
16.
Campana, W. Marie, Elisabetta Mantuano, Pardis Azmoon, et al.. (2017). Ionotropic glutamate receptors activate cell signaling in response to glutamate in Schwann cells. The FASEB Journal. 31(4). 1744–1755. 27 indexed citations
17.
Mantuano, Elisabetta, Pardis Azmoon, Coralie Brifault, et al.. (2017). Tissue-type plasminogen activator regulates macrophage activation and innate immunity. Blood. 130(11). 1364–1374. 49 indexed citations
18.
Mantuano, Elisabetta, Coralie Brifault, Michael S. Lam, et al.. (2016). LDL receptor-related protein-1 regulates NFκB and microRNA-155 in macrophages to control the inflammatory response. Proceedings of the National Academy of Sciences. 113(5). 1369–1374. 104 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026